- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03215966
A Study to Compare the Macitentan-tadalafil Fixed Dose Combination Tablet Relative to the Concomitant Administration of the Reference Tablets of Macitentan and Tadalafil in Healthy Subjects
November 8, 2017 updated by: Actelion
Single-center, Open-label, Single-dose, Two-period, Randomized, Crossover, Phase I Study to Demonstrate Bioequivalence Between a Fixed Dose Combination Product Formulation of Macitentan/Tadalafil (10 mg/40 mg) and the Free Combination of 10 mg Macitentan (Opsumit®) and 40 mg Tadalafil (Adcirca®) in Healthy Male and Female Subjects
The primary objective of this study is to demonstrate that macitentan and tadalafil administered as a fixed combination is bioequivalent to both compounds given as separate tablets given at the same doses as in the fixed combination (i.e.
whether the amounts of macitentan and tadalfil which reach the blood are comparable).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
38
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Mannheim, Germany, 68167
- CRS Clinical Research Services Mannheim
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 53 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Key Inclusion Criteria:
- Signed informed consent
- Male and female subjects aged between 18 and 55 years (inclusive) at screening
- Healthy on the basis of the physical examination, vital signs, 12-lead ECG, and laboratory tests performed at screening
- Women must have a negative serum pregnancy test at screening and a negative urine pregnancy test on Day-1 or must be of non-childbearing potential.
- Body mass index (BMI) of 18.0 to 30.0 kg/m2 (inclusive) at screening
- Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and pulse rate 45-90 bpm (inclusive)
Key Exclusion Criteria:
- Known hypersensitivity to any active substance or drugs of the same class, or any excipients of the drug formulation(s)
- History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study treatment(s)
- Values of hepatic aminotransferase (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]) > 3 X upper limit of normal at screening
- Loss of vision in one eye because of non-arteritic anterior ischemic optic neuropathy
- Known hereditary degenerative retinal disorders, including retinitis pigmentosa
- Priapism and anatomical deformation of the penis
- Previous history of fainting, collapse, syncope, orthostatic hypotension, or vasovagal reactions
- Treatment with another investigational drug within 3 months prior to screening or participation in more than 4 investigational drug studies within 1 year prior to screening
- Excessive caffeine consumption, defined as > or = 800 mg per day at screening.
- Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) within 3 months prior to screening and inability to refrain from nicotine intake from screening until end-of-study (EOS; washout period included)
- Previous treatment with any prescribed medications (including vaccines) or over the counter (OTC) medications within 3 weeks prior to first study treatment administration.
- Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sequence A/B
Subjects receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 1, then after a washout period of at least 7 days they receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 2
|
Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
Film-coated tablets for oral administration formulated at a strength of 10 mg
Other Names:
Film-coated tablets for oral administration formulated at a strength of 20 mg
|
Experimental: Sequence B/A
Subjects receive one tablet of macitentan (Opsumit®) and two tablets of tadalafil (Adcirca®) during Period 1, then after a washout period of at least 7 days, they receive one tablet of macitentan / tadalafil FDC (fixed dose combination) during Period 2
|
Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
Film-coated tablets for oral administration formulated at a strength of 10 mg
Other Names:
Film-coated tablets for oral administration formulated at a strength of 20 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum plasma concentration (Cmax) of macitentan and tadalafil
Time Frame: Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
The measured individual plasma concentrations of macitentan and tadalafil are used to directly obtain Cmax
|
Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Area under the plasma concentration-time curve from 0 to time t [AUC(0-t)] of macitentan and tadalafil
Time Frame: Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
AUC(0-t) is the area calculated from the concentration-time profile of macitentan and tadalafil, from time 0 to to time t of the last measured concentration above the limit of quantification
|
Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Area under the plasma concentration-time curve to infinitiy [AUC(0-inf)] of macitentan and tadalafil
Time Frame: Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
AUC(0-inf) is the area calculated from the concentration-time profile of macitentan and tadalafil, from time 0 to extrapolated infinite time
|
Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
maximal plasma concentration (Cmax) of ACT-132577
Time Frame: Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Cmax of the active metabolite of macitentan, ACT-132577, is measured directly from the plasma concentrations of ACT-132577
|
Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Area under the plasma concentration-time curve from 0 to time t [AUC(0-t)] of ACT-132577
Time Frame: Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
AUC(0-t) of the active metabolite of macitentan, ACT-132577, is calculated from the concentration-time profile of ACT-132577 from time 0 to time t of the last measured concentration above the limit of quantification
|
Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Area under the plasma concentration-time curve to infinity [AUC(0-inf)] of ACT-132577
Time Frame: Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
AUC(0-inf) of the active metabolite of macitentan, ACT-132577, is calculated from the concentration-time profile of ACT-132577 from time 0 to extrapolated infinite time
|
Blood samples for pharmacokinetic evaluations are collected at selected time points from Baseline (pre-dose) to 216 hours post-dose of each study period
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: JP Jones, Actelion
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 7, 2017
Primary Completion (Actual)
September 24, 2017
Study Completion (Actual)
September 24, 2017
Study Registration Dates
First Submitted
July 11, 2017
First Submitted That Met QC Criteria
July 11, 2017
First Posted (Actual)
July 12, 2017
Study Record Updates
Last Update Posted (Actual)
November 9, 2017
Last Update Submitted That Met QC Criteria
November 8, 2017
Last Verified
November 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AC-077-103
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
Lund UniversityCompletedHealthy Subjects | Diet, HealthySweden
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHealthy | Healthy Subjects | ImmunosuppressionUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
NeuShen TherapeuticsNot yet recruiting
-
GEN İlaç ve Sağlık Ürünleri A.Ş.Sulfateq B.V.Recruiting
-
Bio-innova Co., LtdNot yet recruiting
-
Bio-innova Co., LtdNot yet recruiting
Clinical Trials on Macitentan / tadalafil FDC
-
ActelionActive, not recruitingPulmonary Arterial Hypertension (PAH) (WHO Group 1 PH)United States, Japan, Taiwan, Turkey, Canada, China, Germany, Spain, Italy, Malaysia, Hungary, Russian Federation, Brazil, Australia, Bulgaria, Czechia, Mexico, Poland, South Africa
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
ActelionRecruitingHypertension, PulmonaryKorea, Republic of, Taiwan, Poland, Bulgaria, Ukraine, Belgium, South Africa, Belarus, Russian Federation
-
ActelionTerminated
-
Amsterdam UMC, location VUmcUnknownPulmonary Arterial HypertensionNetherlands
-
GlaxoSmithKlineHammersmith Medicines Research; Covance HarrogateCompletedHypertension, PulmonaryUnited Kingdom
-
University of California, Los AngelesWithdrawnLung Transplant RejectionUnited States
-
Janssen Pharmaceutical K.K.Completed